摘要
目的 探讨ACEI类药 -西拉普利对 2型糖尿病并肾病患者的尿α1,β2 MG ,尿白蛋白的影响。方法 患者均伴有DM肾病 (DN) ,随机分成两组 ,治疗组 (2 8例 )服西拉普利 ,对照组 (2 8例 )服钙离子拮抗剂硝苯地平控释片。分别于服药前及后 4周、8周、16周用放射免疫法 (RIA)测定患者尿α1 MG、β2 MG及Alb。结果 西拉普利有明显降低 2型DM肾病患者尿α1 MG、β2 MG的排出。且对α1 MG的降低作用更显著 (P <0 .0 1)。结论 西拉普利适用于DN患者 ,尤其是α1
Objective To study the effect of angiotensin converting enzyme inhibitor(ACEI) cilazapril on urine α 1 microglobulin(α 1 MG) and β 2 microglobulin(β 2 MG) in type 2 diabetes millitus(DM) with diabetic nephrosis(DN). Methods 56 cases of type 2 DM patients associated with DN were divided into 2 groups: cilazapril group 28 cases and nifedipine(GITS) groups 28 cases. The α 1 MG and β 2 MG and albuminuria(Alb) were measured by the method of ratio immunoassay(RIA) before and after 4,8,16 weeks medication. Urine excretion of α 1 , β 2 MG, and Alb were determined before and after of treatment. Results Cilazapril reduced α 1 MG and β 2 MG significantly,and the α 1 MG reduced more significant( P< 0.01). Conclusion The cilazepril are fited for treating the DN patients with the higher α 1 MG excretion.
出处
《高血压杂志》
CSCD
2001年第3期194-196,共3页
Chinese Journal of Hypertension
